Search

In recent years, more importance has begun to be attached to emotional life, especially in the case of doctors dealing with the death of patients. The care and death of seriously ill patients has a strong emotional impact on doctors. The grief caused by the death of patients affects not only the personal life of physicians but also their professional life and, if left unaddressed, can lead to burnout and impact both patient care and the doctor-patient relationship. Aim: The aim of the study was to identify the emotional experiences of physicians coping with the death of patients and to understand how it affects them. The overall objective of the study was to reduce the emotional impact of patients' death on physicians by normalizing the loss and using coping methods. Material and Methods: A retrospective study was conducted between March and June 2023, which consisted of a 21-question questionnaire distributed online and addressed to physicians who had experienced at least once in their lifetime the death of a patient. The research questions focused mainly on the impact of patient death on the personal and professional lives of doctors. A total of 124 physician respondents were included in the study. Results: The frequency with which physicians experience patient death differs by specialty and professional experience. The medical specialties where physicians face the most patients who die are oncology, internal medicine, cardiology, anesthesiology and intensive care. The most common emotions that physicians encounter after the death of a patient are: acceptance, anxiety, depression, disappointment, exhaustion, frustration, anger, helplessness, stress, sadness, guilt. Conclusions: The death of a patient can have a significant emotional impact on physicians and varies from physician to physician. The emotions generated by the death of a patient can influence physicians' personal and professional lives to varying degrees. In order to prevent burnout, doctors should be more aware of their own emotional experiences related to the death of a patient and seek help from colleagues or a psychologist to keep themselves in the best possible physical and emotional state. [ABSTRACT FROM AUTHOR]

Copyright of Oncolog-Hematolog is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Oncolog-Hematolog is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Oncolog-Hematolog is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Oncolog-Hematolog is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Farmacia is the property of Societatea de Stiinte Farmaceutice Romania and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Oncolog-Hematolog is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Nutrition is an indispensable element in everyone’s existence, being essential for preventing complications in oncological patients. Weight loss and malnutrition are factors of poor prognosis, multimodal cancer therapy being inefficient in patients with nutritional deficiency. Nutritional support in cancer patients is one of the main cornerstones of curative cancer treatment, but also represents an indispensable component of palliative care. Enteral nutritional support can assure a proper metabolic status in patients with normal digestive system who can no longer feed per os. Parenteral nutrition is initiated in patients with severe digestive issues. Enteral nutritional support can be provided by gastrostomy or jejunostomy performed with formal surgery or percutaneous endoscopic gastrostomy (PEG) and other similar procedures. After the parenteral nutrition devices is installed, nutritional formulae are directly introduced in the patient’s stomach. There are different formulae, based on the patient’s needs, and different volumes introduced per meal, depending on the procedure (PEG allows a larger volume than classic gastrostomy). The parenteral nutritional support requires a central venous catheter and multiple formulae containing amino acids, glucose, lipids, salts and vitamins that are directly introduced in the patient’s blood flow. The main disadvantage of this procedure is that it can be sustained for maximum 15 days. A significant percent of the patients diagnosed with cervical cancer will require enteral nutritional support during oncological treatment and one year afterwards. PEG is a superior to classic gastrostomy,and it represents the ideal choice when it comes to oncological patients at risk of malnutrition. The devices used in this procedure allow a faster recovery, they have a low rate of complication, they are economically advantageous and the patient can resume the nutrition in 24-48 hours. [ABSTRACT FROM AUTHOR]

Copyright of Medic.ro is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

A major public health issue, colon cancer can only benefit from surgery as a form of curative treatment, and this only if diagnosed relatively early. Even in those happy cases where the patient undergoes surgery at the right time, there are no guarantees for a good outcome from an oncological point of view, both on medium and long term. This paper is looking to evaluate especially those neoplastic complications that may arise in these patients. This retrospective, single-centre study included 138 patients with colon cancer who have undergone surgery in the First Surgical Department of the “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology, Bucharest, over the course of two years, between January 2015 and December 2016. This study included only those patients confirmed with colon cancer through a histopathological exam, with an initial localization of the tumor strictly in the colon and where curative surgical treatment was possible. Those patients in which tumors were localized in the rectum as well, along with those not having undergone surgery or where data were incomplete had been excluded from our study. Out of the 138 patients included in this study, 45 presented neoplastic complications after an interval of time, variable in length, since the initial surgery. For all those patients included in the study, the following criteria were evaluated: sex, age, symptoms at the onset of the disease, localization of the tumor, complications at the onset, type of surgical intervention, adjuvant therapy, type of neoplastic complications, their diagnosis and management. This study’s findings are consistent with the available data regarding colon cancer, its evolution and the evolution of complications. In the majority of cases, the surgical interventions had a curative goal from an oncological point of view, as later confirmed through histopathological examinations of the resected specimens. The incidence rate after colon cancer surgery was 46.9%, including both local recurrences, locoregional recurrences, adenopathic blocks or metastases, as well as metachronous cancer or a second, extracolonic, cancer. The management of neoplastic complications has, at most times, consisted of adapted surgical resections (77.77%) and adjuvant therapy. Our study confirms the rather high incidence rate of neoplastic complications after radical colon cancer surgery and underlines the importance of postoperative follow-ups of patients through colonoscopy, medical imaging techniques and monitoring of tumor markers. As previously shown in other studies, we consider that this monitoring programme is mandatory especially in the first two years after surgery, the time interval when most neoplastic complications may arise. We consider that the future studies should focus on discovering certain specific markers that could allow identifying a subset of patients who could benefit from more intense postoperative follow-ups, as well as finding certain biological markers that could allow the early identification of recurrences, in potentially curable stages. [ABSTRACT FROM AUTHOR]

As well as being known as one of the deadliest gynaecological diseases, ovarian cancer is frequently discovered in advanced stages, the patients already presenting peritoneal metastases when diagnosed. Intestinal occlusion may occur at any moment during the evolution of the disease, but is being met more frequently in the advanced stages of the disease, when it can lead to patient’s death. This study aims to review the treatment options of intestinal occlusion in ovarian cancer patients. This retrospective, single-centre study included 240 patients diagnosed with ovarian cancer, treated in the First Surgical Department of the “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology, Bucharest, between January 2015 and December 2017. A series of parameters were analyzed, such as age, pathological type, grade of differentiation, tumor dimensions, localization of metastases, number of episodes of intestinal occlusions during the evolution of the disease, therapeutic modalities etc. Out of the 240 patients included in the study, 32 presented with intestinal occlusion during the evolution of the disease, out of which only two patients were under the age of 40 years old. One third of the patients presented with intestinal involvement at the moment of diagnosis. Regarding the number of episodes of intestinal occlusion during the evolution, 24 out of the 32 patients had a single episode. The optimal therapeutic approach is the surgical treatment, but this was possible only in 73% of cases. Nevertheless, surgical interventions were not seeking a curative goal and were accompanied by complex measures of palliative care. In the 32 patients included in the study, we have found a total of 41 episodes of intestinal occlusion, identified and treated at the “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology, out of which 30 episodes benefited from surgical treatment. While still being, unfortunately, discovered late, ovarian cancer is mostly diagnosed during the stage of complications, intestinal occlusion being fairly frequent and life-threatening. The available therapeutic approaches are centred on the management of symptoms and on ensuring a quality of life as high as possible for the time left, the surgical interventions, even palliative, being the only option that might prolong survival when feasible. [ABSTRACT FROM AUTHOR]